SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (515)2/3/2000 3:15:00 PM
From: Pseudo Biologist  Read Replies (1) | Respond to of 666
 
Parking the older Coulter patent:

164.195.100.11

(filed September 1993)

It may be that Coulter's IP blocks the use of radiometric dosing; something they have pushed as an advantage of Bexxar treatment versus others. Of course, some think this is just a "feature." -g-

Time to add a patent section to the shrine?

PB



To: biowa who wrote (515)2/3/2000 9:33:00 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 666
 
Biowa,

No, I didn't said that you or anyone else proclaimed victory in regards the CLTR patents. Only that one has to be very careful and evaluate all side, as you did. And thanks for that.

Once, I was sure that NXTR will prevail in LIPO patents litigation, and was wrong. Lawyers have last word, otherwise how they will make *muco* $$$$?

BTW, CLTR is reacting nicely on news. :)

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News